TO TORNTPHARM
Torrent Pharmaceuticals Q3 2026
TOTORNTPHARM

Torrent Pharmaceuticals Q3 FY26 results (Oct–Dec 2025) and concall

Healthcare · Concall AI · Call held 13 Feb 2026

Management summary

  • Torrent Pharma delivered a strong Q3 FY26 performance characterized by double-digit growth in its core branded markets of India and Brazil.
  • The quarter was headlined by the acquisition of a controlling stake in JB Pharma, which is expected to drive significant cost synergies and margin expansion over the next three years.
  • While the Germany business faced supply chain disruptions, the US business showed signs of recovery through new launches, and the company remains focused on scaling its chronic therapy presence.

Source: Inve concall analysis and management guidance record.

What they filed

Q3 FY26: revenue up 9.3%, net profit up 19.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue2,377 2,433 2,616 2,762 2,599 +9%
EBITDA887 868 979 1,072 1,000 +13%
Net profit485 474 551 597 577 +19%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Margin

  • JB Pharma Cost Synergies Margin · next 2-3 years · High confidence ₹400-450 crores

Headcount

  • India Field Force Strength Headcount · FY26 · High confidence 7,000+

    From 6,800 today

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

1 direct, 1 evasive
JB Pharma Consolidation and Synergies Direct
consolidation, Damayanti, is line-by-line only. So, effective from 21st January till 31st March, the Quarter 4 numbers will include JB numbers.

Clarifies that the acquisition will immediately impact the P&L on a consolidated basis, allowing investors to model the full impact of JB's financials.

Asked by Damayanti Kerai, HSBC

Germany Supply Disruption Timeline Evasive
I cannot give a timeline because our supplier is caught up in regulatory issues... it will take at least 3 to 4 quarters to get an alternate supplier on board.

Highlights a significant near-term risk in the European business with no immediate resolution, potentially dragging down overall growth for the next year.

Asked by Damayanti Kerai, HSBC

Unlock risks & concerns, Q4 FY26 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 4 risks, concerns & management red flags
  • Watchlist triggers for Q4 FY26
  • +3 more guidance targets & verbatim management quotes
  • +1 more analyst Q&A exchange & evasion checks
  • Full section-by-section call narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image